- Home
- TBN vs VNDA Comparison
TBN vs VNDA Comparison
Compare TBN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBN
- VNDA
- Stock Information
- Founded
- TBN 2009
- VNDA 2002
- Country
- TBN Australia
- VNDA United States
- Employees
- TBN N/A
- VNDA N/A
- Industry
- TBN
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- TBN
- VNDA Health Care
- Exchange
- TBN NYSE
- VNDA Nasdaq
- Market Cap
- TBN 332.7M
- VNDA 261.7M
- IPO Year
- TBN 2024
- VNDA 2006
- Fundamental
- Price
- TBN $20.00
- VNDA $4.89
- Analyst Decision
- TBN Buy
- VNDA Strong Buy
- Analyst Count
- TBN 4
- VNDA 3
- Target Price
- TBN $35.00
- VNDA $15.33
- AVG Volume (30 Days)
- TBN 38.4K
- VNDA 422.8K
- Earning Date
- TBN 05-14-2025
- VNDA 07-30-2025
- Dividend Yield
- TBN N/A
- VNDA N/A
- EPS Growth
- TBN N/A
- VNDA N/A
- EPS
- TBN N/A
- VNDA N/A
- Revenue
- TBN N/A
- VNDA $201,351,000.00
- Revenue This Year
- TBN N/A
- VNDA $16.86
- Revenue Next Year
- TBN N/A
- VNDA $39.78
- P/E Ratio
- TBN N/A
- VNDA N/A
- Revenue Growth
- TBN N/A
- VNDA 13.37
- 52 Week Low
- TBN $15.75
- VNDA $3.81
- 52 Week High
- TBN $34.50
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- TBN N/A
- VNDA 64.92
- Support Level
- TBN N/A
- VNDA $4.66
- Resistance Level
- TBN N/A
- VNDA $4.95
- Average True Range (ATR)
- TBN 0.00
- VNDA 0.15
- MACD
- TBN 0.00
- VNDA 0.02
- Stochastic Oscillator
- TBN 0.00
- VNDA 89.47
About TBN TAMBORAN RESOURCES CORPORATION
Tamboran Resources Corp is a gas company focused on supporting the Net Zero CO2 energy transition in Australia and Asia-Pacific through developing low CO2 unconventional gas resources in the Australian Northern Territory.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.